JP2012082227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012082227A5 JP2012082227A5 JP2012014178A JP2012014178A JP2012082227A5 JP 2012082227 A5 JP2012082227 A5 JP 2012082227A5 JP 2012014178 A JP2012014178 A JP 2012014178A JP 2012014178 A JP2012014178 A JP 2012014178A JP 2012082227 A5 JP2012082227 A5 JP 2012082227A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- neoplastic agent
- agent
- protective
- neoplastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 19
- 230000001681 protective effect Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 5
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- HQVAVYYAPZDXHV-UHFFFAOYSA-N 2-nitro-1h-imidazole;hydrobromide Chemical compound Br.[O-][N+](=O)C1=NC=CN1 HQVAVYYAPZDXHV-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45884503P | 2003-03-28 | 2003-03-28 | |
| US60/458,845 | 2003-03-28 | ||
| US46528103P | 2003-04-21 | 2003-04-21 | |
| US60/465,281 | 2003-04-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509466A Division JP2006521409A (ja) | 2003-03-28 | 2004-03-29 | 癌を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012082227A JP2012082227A (ja) | 2012-04-26 |
| JP2012082227A5 true JP2012082227A5 (enExample) | 2013-03-07 |
| JP5572644B2 JP5572644B2 (ja) | 2014-08-13 |
Family
ID=33135116
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509466A Ceased JP2006521409A (ja) | 2003-03-28 | 2004-03-29 | 癌を処置するための組成物および方法 |
| JP2012014178A Expired - Fee Related JP5572644B2 (ja) | 2003-03-28 | 2012-01-26 | 癌を処置するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509466A Ceased JP2006521409A (ja) | 2003-03-28 | 2004-03-29 | 癌を処置するための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7550496B2 (enExample) |
| EP (2) | EP2671581B8 (enExample) |
| JP (2) | JP2006521409A (enExample) |
| KR (2) | KR20050113670A (enExample) |
| CN (2) | CN102161679A (enExample) |
| AU (1) | AU2004226338C1 (enExample) |
| CA (1) | CA2520000C (enExample) |
| ES (1) | ES2759176T3 (enExample) |
| IL (1) | IL170970A (enExample) |
| MX (1) | MXPA05010407A (enExample) |
| NO (1) | NO336266B1 (enExample) |
| NZ (1) | NZ543223A (enExample) |
| WO (1) | WO2004087075A2 (enExample) |
| ZA (1) | ZA200507752B (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US7691838B2 (en) | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| DE50305909D1 (de) * | 2003-10-13 | 2007-01-18 | Salama Zoser B | Pharmazeutische Zusammensetzung umfassend Oxoplatin und dessen Salze |
| US20080132458A1 (en) * | 2004-03-10 | 2008-06-05 | Threshold Pharmaceuticals, Inc. | Hypoxia-Activated Anti-Cancer Agents |
| GB0421296D0 (en) * | 2004-09-24 | 2004-10-27 | Angiogene Pharm Ltd | Bioreductively-activated prodrugs |
| US7208611B2 (en) | 2005-02-23 | 2007-04-24 | Xenoport, Inc. | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use |
| JP2006282653A (ja) * | 2005-03-10 | 2006-10-19 | Kyoto Univ | 標的部位で選択的に活性化される新規化合物およびその利用 |
| BRPI0612845A8 (pt) | 2005-06-29 | 2018-01-23 | Threshold Pharmaceuticals Inc | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador |
| ES2884044T3 (es) * | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
| WO2008115499A1 (en) | 2007-03-19 | 2008-09-25 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon | Mannich base n-oxide drugs |
| WO2008151253A1 (en) * | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| WO2009018163A1 (en) * | 2007-07-27 | 2009-02-05 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of anthracyclines |
| WO2009033165A1 (en) * | 2007-09-06 | 2009-03-12 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of bis-alkylating agents |
| US20090118031A1 (en) * | 2007-11-01 | 2009-05-07 | Qualizza Gregory K | Shaft Structure with Configurable Bending Profile |
| US8946275B2 (en) | 2008-10-21 | 2015-02-03 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| WO2010073126A2 (en) * | 2008-12-22 | 2010-07-01 | The Governors Of The University Of Alberta | Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof |
| CN101538256B (zh) * | 2009-04-28 | 2014-05-21 | 沈阳药科大学 | 3，4-二芳基呋喃-2，5-二酮类衍生物与3，4-二芳基-1h-吡咯-2，5-二酮类衍生物及其用途 |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| WO2012009288A2 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| EP2648738A2 (en) * | 2010-12-06 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents |
| US9402820B2 (en) | 2011-04-22 | 2016-08-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors |
| CN102260273B (zh) * | 2011-05-13 | 2015-04-22 | 兰州大学 | 脱氧鬼臼与5-氟尿嘧啶的拼合物及其制备与用途 |
| JP2015500885A (ja) | 2011-12-22 | 2015-01-08 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
| LT2797416T (lt) | 2011-12-28 | 2017-10-25 | Global Blood Therapeutics, Inc. | Pakeistieji benzaldehido junginiai ir jų panaudojimo būdai, didinant audinių aprūpinimą deguonimi |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| CN104427984A (zh) | 2012-01-20 | 2015-03-18 | D·布朗 | 包括二脱水半乳糖醇和类似物的经取代的己糖醇类于治疗包括多形性胶质母细胞瘤和成神经管细胞瘤的肿瘤疾病和癌症干细胞的用途 |
| US9655975B2 (en) | 2012-02-13 | 2017-05-23 | University Of Tsukuba | Prodrug using nitroimidazole |
| CN104204035B (zh) | 2012-03-30 | 2017-05-24 | 宇部兴产株式会社 | 具有封端基团的聚轮烷的制造方法 |
| WO2014058974A1 (en) * | 2012-10-10 | 2014-04-17 | Emory University | Methods of managing inflammation using glycolysis pathway inhibitors |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US10037382B2 (en) | 2012-10-29 | 2018-07-31 | Kyocera Corporation | Surface acoustic wave sensor |
| CN105050619A (zh) | 2012-12-03 | 2015-11-11 | 梅里马克制药公司 | 用于治疗her2-阳性癌症的组合疗法 |
| EP2777694A1 (en) | 2013-03-14 | 2014-09-17 | Brij P. Giri | Hypoxia-Targeted Polymeric Micelles for Cancer Therapy and Imaging |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| JP6355711B2 (ja) | 2013-03-15 | 2018-07-11 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| JP6463327B2 (ja) | 2013-03-15 | 2019-01-30 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| US9868960B2 (en) | 2013-05-10 | 2018-01-16 | National Brain Research Centre | Placental like alkaline phosphatase (PLAP) promoter mediated cell targeting |
| JP2016528217A (ja) | 2013-07-26 | 2016-09-15 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
| EP3024456A4 (en) | 2013-07-26 | 2017-04-12 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| CN104434876B (zh) * | 2013-09-13 | 2018-04-27 | 布里吉·P·吉里 | 用于癌症疗法及成像的缺氧-标靶聚合微胞 |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN114213390A (zh) | 2014-02-07 | 2022-03-22 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2016011195A1 (en) | 2014-07-17 | 2016-01-21 | Threshold Pharmaceuticals, Inc. | Th-302 solid forms and methods related thereto |
| US10364261B2 (en) | 2015-03-10 | 2019-07-30 | Obi Pharma, Inc. | DNA alkylating agents |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| EP3277381B1 (en) | 2015-04-02 | 2026-01-07 | Obi Pharma, Inc. | Nitrobenzyl derivatives of anti-cancer agents |
| US20180169064A1 (en) | 2015-06-24 | 2018-06-21 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
| AU2016323770A1 (en) | 2015-09-16 | 2018-03-29 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
| CN105250325A (zh) * | 2015-10-28 | 2016-01-20 | 淄博齐鼎立专利信息咨询有限公司 | Demissine在制备治疗肾癌药物中的应用 |
| SI3383392T1 (sl) | 2015-12-04 | 2025-10-30 | Global Blood Therapeutics, Inc. | Režimi odmerjanja za 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehid |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| CN106554375B (zh) * | 2016-06-08 | 2019-10-18 | 浙江海正药业股份有限公司 | 一种蒽环类化合物、其制备方法及其用途 |
| US20210369746A1 (en) | 2016-08-01 | 2021-12-02 | Molecular Templates, Inc. | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| CN118948828A (zh) | 2017-03-15 | 2024-11-15 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法 |
| CN106977501A (zh) * | 2017-03-20 | 2017-07-25 | 华东师范大学 | 一种基于2‑硝基咪唑‑1‑烷基醇的低氧激活前药 |
| CN107417672A (zh) * | 2017-04-12 | 2017-12-01 | 华东师范大学 | 一种基于2,2‑二甲基‑3‑（2‑硝基咪唑基）丙酸的低氧激活前药 |
| JP2020534289A (ja) * | 2017-09-14 | 2020-11-26 | ランケナー インスティテュート フォー メディカル リサーチ | がんの治療のための方法および組成物 |
| BR112020015745A2 (pt) | 2018-02-02 | 2020-12-08 | Maverix Oncology, Inc. | Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina |
| JP7372252B2 (ja) | 2018-03-16 | 2023-10-31 | ディーエフビー ソリア リミテッド ライアビリティ カンパニー | タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法 |
| WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| KR102747229B1 (ko) | 2021-08-10 | 2024-12-31 | 경북대학교 산학협력단 | 두경부암의 예후 예측을 위한 암 관련 섬유아세포의 바이오마커 |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250387419A1 (en) | 2021-08-27 | 2025-12-25 | Ascentawits Pharmaceuticals, Ltd. | Parp inhibitor-resistant patient treated with th-302 |
| CN113968867A (zh) * | 2021-11-10 | 2022-01-25 | 聊城大学 | 一种喜树碱类前药及其用途 |
| CN118475349A (zh) * | 2021-12-21 | 2024-08-09 | 国立大学法人筑波大学 | 抗癌药的低氧响应性前药与放射治疗的联合疗法、以及新型低氧响应性前药 |
| CN114617876B (zh) * | 2022-01-28 | 2023-04-07 | 四川大学华西医院 | 一种抗肿瘤联合用药物 |
| CN116675620B (zh) * | 2022-02-22 | 2025-01-10 | 东南大学 | No供体化合物及其制备方法、药物组合物和应用 |
| CN118829436A (zh) | 2022-03-15 | 2024-10-22 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| EP4509127A1 (en) | 2022-04-15 | 2025-02-19 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4674418A1 (en) | 2023-02-27 | 2026-01-07 | Ascentawits Pharmaceuticals, Ltd. | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652579A (en) | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
| DE2229223C3 (de) | 1971-07-30 | 1975-12-18 | Gruppo Lepetit S.P.A., Mailand (Italien) | 2-Nitro-S-imidazol-Derivate und Verfahren zu deren Herstellung |
| US4921963A (en) | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| JPH0819111B2 (ja) | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
| US5403932A (en) | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| US4908356A (en) | 1988-05-25 | 1990-03-13 | Research Corporation Technologies, Inc. | Aldophosphamide derivatives useful as antitumor agents |
| US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
| DE3835772A1 (de) | 1988-10-20 | 1990-04-26 | Deutsches Krebsforsch | Tumorhemmende saccharid-konjugate |
| KR927003539A (ko) | 1990-01-26 | 1992-12-18 | 스즈끼 쯔네시 | 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제 |
| US5233031A (en) | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
| JP4115514B2 (ja) | 1991-10-23 | 2008-07-09 | キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド | Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ |
| US5750782A (en) | 1992-11-27 | 1998-05-12 | Cancer Research Campaign Technology Limited | Nitroaniline derivatives and their use as anti-tumour agents |
| US5306727A (en) | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| WO1994027954A1 (en) | 1993-05-25 | 1994-12-08 | Auckland Uniservices Limited | Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents |
| DE69425356T2 (de) | 1993-09-22 | 2002-04-18 | Hoechst Ag | Pro-Prodrugs, ihre Herstellung und Anwendung |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5659061A (en) | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
| GB9516943D0 (en) | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
| GB9526391D0 (en) | 1995-12-22 | 1996-02-21 | Diversey Equipment Technologie | Dispenser |
| US6218519B1 (en) | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US6251933B1 (en) | 1996-12-13 | 2001-06-26 | The Cancer Research Campaign Technology Limited | Seco precursors of cyclopropylindolines and their use as prodrugs |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| US6240925B1 (en) | 1999-03-23 | 2001-06-05 | Cynosure, Inc. | Photothermal vascular targeting with bioreductive agents |
| GB9909612D0 (en) * | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| HK1043058A1 (zh) | 1999-05-24 | 2002-09-06 | Southern Research Institute | 异环磷酰胺芥子类似物及其用途 |
| WO2001004130A1 (en) | 1999-07-14 | 2001-01-18 | Purdue Research Foundation | Phosphoramide compounds |
| CA2397203A1 (en) | 2000-03-31 | 2001-10-11 | Sandra C. Tobias | Phosphoramidate prodrugs |
| JP2002046334A (ja) | 2000-08-04 | 2002-02-12 | Riso Kagaku Corp | 孔版印刷装置及び該装置の印刷ドラム |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US6506739B1 (en) | 2001-05-01 | 2003-01-14 | Telik, Inc. | Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents |
| NZ529788A (en) | 2001-05-31 | 2003-12-19 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR20030067275A (ko) | 2002-02-07 | 2003-08-14 | 주식회사 하이폭시 | 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제 |
| JP4187096B2 (ja) | 2003-01-15 | 2008-11-26 | 独立行政法人科学技術振興機構 | ３次元フォトニック結晶製造方法 |
| GB0306908D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Bioreductively activated stilbene prodrugs |
| GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US6855695B2 (en) | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
| ES2389809T3 (es) | 2004-02-06 | 2012-10-31 | Threshold Pharmaceuticals, Inc. | Terapias anticancerosas |
| AU2005309761A1 (en) | 2004-11-22 | 2006-06-01 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer agents and prodrugs thereof |
| WO2008011588A2 (en) | 2006-07-20 | 2008-01-24 | Threshold Pharmaceuticals, Inc. | Glycoconjugates of phosphoramidate alkylators for treatment of cancer |
| WO2008076826A1 (en) | 2006-12-13 | 2008-06-26 | Threshold Pharmaceuticals, Inc. | Pyrophosphoramide alkylators |
| ES2884044T3 (es) | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
-
2004
- 2004-03-28 ZA ZA200507752A patent/ZA200507752B/en unknown
- 2004-03-29 EP EP13178249.2A patent/EP2671581B8/en not_active Expired - Lifetime
- 2004-03-29 KR KR1020057018367A patent/KR20050113670A/ko not_active Withdrawn
- 2004-03-29 MX MXPA05010407A patent/MXPA05010407A/es active IP Right Grant
- 2004-03-29 US US10/549,545 patent/US7550496B2/en not_active Expired - Lifetime
- 2004-03-29 ES ES13178249T patent/ES2759176T3/es not_active Expired - Lifetime
- 2004-03-29 KR KR1020127002215A patent/KR101198526B1/ko not_active Expired - Lifetime
- 2004-03-29 EP EP04749522A patent/EP1622608A4/en not_active Withdrawn
- 2004-03-29 AU AU2004226338A patent/AU2004226338C1/en not_active Expired
- 2004-03-29 WO PCT/US2004/009667 patent/WO2004087075A2/en not_active Ceased
- 2004-03-29 CN CN2010105956028A patent/CN102161679A/zh active Pending
- 2004-03-29 NZ NZ543223A patent/NZ543223A/en not_active IP Right Cessation
- 2004-03-29 CN CNA2004800132768A patent/CN1791403A/zh active Pending
- 2004-03-29 CA CA2520000A patent/CA2520000C/en not_active Expired - Lifetime
- 2004-03-29 JP JP2006509466A patent/JP2006521409A/ja not_active Ceased
-
2005
- 2005-09-19 IL IL170970A patent/IL170970A/en active IP Right Grant
- 2005-10-26 NO NO20054988A patent/NO336266B1/no not_active IP Right Cessation
-
2009
- 2009-06-12 US US12/484,104 patent/US8299088B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 JP JP2012014178A patent/JP5572644B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012082227A5 (enExample) | ||
| JP7179357B2 (ja) | ２－アミノ－キノリン誘導体 | |
| JP6893501B2 (ja) | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン | |
| RU2697707C9 (ru) | Процессы приготовления производных соединений дигидропиримидина и их промежуточных продуктов | |
| TWI607007B (zh) | ４－胺基－咪唑并喹啉化合物 | |
| JP2010501572A5 (enExample) | ||
| EP2367809B1 (en) | Derivatives of [(3-hydroxy-4 pyron-2-yl)methyl]-amine and use thereof as anti-neoplastic drugs | |
| JP2011506588A5 (enExample) | ||
| ES2923529T3 (es) | Proceso para fabricar moduladores de somatostatina | |
| JP2016512823A5 (enExample) | ||
| JP2010513494A5 (enExample) | ||
| JP2013503846A5 (enExample) | ||
| JP2012504628A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| EA201270550A1 (ru) | Процесс получения соединений для применения в качестве ингибиторов sglt2 | |
| JP2017509689A5 (enExample) | ||
| CN105121439A (zh) | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 | |
| US20110178041A1 (en) | Heterocyclic biaryl derivative and pde inhibitor comprising same as active ingredient | |
| WO2018154104A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| KR20180128937A (ko) | 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제 | |
| AU2016297607A1 (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HRP20221067T1 (hr) | Postupak priprave 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona i njegovih soli | |
| JP2019504833A5 (enExample) | ||
| RU2008128568A (ru) | (1-азабицикло[3,3,1]нон-4-ил)-[н-индол-5-ил)-гетероарил]-амины, как холинергические лиганды n-achr, предназначенные для лечения психотических и нейродегенеративных нарушений | |
| CN105566260B (zh) | 一种呋塞米的制备方法 |